Welcome to the Daily Picks! Where Uptick staff looks for new companies to feature, giving readers the opportunity to find new possibilities for their investment portfolios.
SNIPF: Snipp Interactive Inc.
Snipp Interactive Inc. (“Snipp”) (TSX VENTURE:SPN)(OTCQX:SNIPF), an international provider of marketing promotions, rebates and loyalty solutions listed on the OTCQX and the TSX Venture Exchange, is pleased to announce that it has extended its loyalty contract with a leading European utility corporation for a term of 3 years with additional functionality on Snipp’s enhanced loyalty platform. The company supplies utilities to approximately 1.2 million households and 100,000 businesses within a single country, and is a subsidiary of an international energy corporation with active operations in over 20 countries. Sales will be recognized incrementally over the life of this contract, adding to our growing stream of recurring revenue.
“Snipp is thrilled to be the loyalty partner for this large European utility company. As we expand across Europe, we are confident that the SnippLoyalty platform will continue to deliver convenient, competitive and innovative long-term loyalty solutions that foster brand affinity by helping consumers turn everyday actions, such as shopping at a grocery store or paying a utility bill, into opportunities to save money and earn valuable rewards. This is the latest example of what we believe is a sustainable trend toward longer-term contracts as customers realize the ongoing value of our programs,” says David Hargreaves, Chief Client Officer at Snipp.
AVMXY: Avita Medical Limited
A US Federal authority charged with supporting development of medical countermeasures for possible mass casualty events has agreed to fund Avita Medical a further $US7.96 million to support the regenerative medicine company in its plans for US market approval and product launch of ReCell®, the Company said today.
Avita Medical Limited, (ASX:AVH; OTCQX:AVMXY) which makes Autologous Cell Harvesting Devices for treatment of burns, chronic wounds and certain aesthetic conditions, said the award supplements the contract executed last September with the Biomedical Advanced Research and Development Authority (BARDA), worth up to $US53.9m. The initial contract with BARDA, an authority under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, includes procurement and various elements of support for late-stage development of ReCell®. The new contract addendum, worth up to $US7.96 million (AUD $11m), commences immediately, giving further operational support to facilitate the overarching objective of BARDA for preparedness via securing effective treatment of burn injuries secondary to detonation of a nuclear device.
Uptick encourages investors to do their own due diligence in determining investment strategies that work for them. Uptick’s opinion is based upon individual company and market factors. Invest at your own risk.